Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has a Major Depressive Episode (MDE), is diagnosed with Major Depressive Disorder (MDD) according to DSM-5® and would benefit from pharmacological treatment with vortioxetine. The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
The patient has a CGI-S ≥4 at screening.
You may not be if
The patient has a significant risk of suicide according to investigator's clinical judgment or has made an actual suicide attempt in the period of 6 months prior to screening.
The patient previously received vortioxetine.
Clareo Health | Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
